ZHONGXING LIAO to Mutation
This is a "connection" page, showing publications ZHONGXING LIAO has written about Mutation.
Connection Strength
0.108
-
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes. Blood Adv. 2024 10 08; 8(19):5215-5224.
Score: 0.058
-
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
Score: 0.026
-
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540.
Score: 0.013
-
Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys. 2020 02 01; 106(2):349-357.
Score: 0.010